Of note, BB use emerged not only in prevention of cancer development per se, but also in prevention of cancer therapy-related cardiotoxicity, as beta-adrenoceptor signalling was shown to share an intricate conundrum with human epidermal growth factor receptor type 2 (ERBB2) in the cardiovascular system, and also in breast cancer.63,64 As a result, the BB carvedilol was shown to prevent ERBB2-blockade-induced cardiotoxicity.65 This evidence concerns the gene ERBB2 and breast carcinoma.